8 results about "Cycloserine" patented technology

This application relates to combination compositions for use in treatment of depression, and which can alleviate the anxiogenic side effects of certain antidepressant and antipsychotic medications. Methods for treatment of depression and medicament side effects, particular anxiety, akathisia, and associated suicidality are also described herein.

The present invention provides a therapeutic or prophylactic agent for amyotrophic lateral sclerosis resulting from aggregation of TDP-43 in nerve cells, the therapeutic or prophylactic agent for amyotrophic lateral sclerosis containing an active ingredient at an amount greater than 100 mg and less than 250 mg, the active ingredient essentially being composed of at least one selected from the group consisting of cycloserine, terizidone, and salts thereof. The active ingredient may be composed of at least one selected from the group consisting of cycloserine, terizidone, and salts thereof. The cycloserine may be D-cycloserine. The cycloserine may be L-cycloserine.

The present invention belongs to the field of pharmaceuticals. Disclosed in the present invention are a class of salt compounds of isosorbide mononitrate derivatives and the use thereof. Salts formed by the isosorbide mononitrate derivatives of the present invention and D-cycloserine exhibit dual activities as a nitric oxide donor and a partial NMDA receptor agonist. The present invention further relates to the use of the salts formed by the isosorbide mononitrate derivatives and D-cycloserine in a drug for treating cerebral stroke or the recovery period of cerebral stroke.

1. Name of the product in this design: Packaging Box (Cycloserine Capsules). 2. Intended use of this design: This design is intended for the packaging, storage, and transportation of pharmaceuticals. 3. Key design features of this design: The key design features of this design are the combination of the product's shape and pattern. 4. The image or photograph that best illustrates the design's key points: a 3D model. 5. The design for which protection is sought includes color.

An inhibitor of aggregation of TDP-43 comprising a combination of at least one compound selected from the group consisting of cycloserine and terizidone and their salts, and edaravone. An inhibitor of the aggregation of TDP-43, which contains at least one compound selected from the group consisting of cycloserine and terizidone, and salts thereof, in combination with edaravone. An inhibitor of aggregation of TDP-43 comprising edaravone in combination with at least one compound selected from the group consisting of cycloserine and terizidone and their salts.

This invention relates to a method (I) for preparing substituted cyclic serine compounds having the chemical formula (I), wherein R 1 It is a C1-C8 alkyl, C1-C8 haloalkyl, C3-C6 cycloalkyl, aryl, or surrounded by one to five Rs. 11 Substituted aryl, or aryl-C1-C4 alkylene, or with one to five R 11 Substituted aryl-C1-C4 alkylene groups; and each R 11 The compounds are independently C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, cyano, or halogen; the invention also relates to intermediates produced by these methods. Compounds having chemical formula (I) are useful intermediates for the production of compounds in the agricultural and pharmaceutical fields.

A therapeutic or prophylactic agent for frontotemporal lobe degeneration accompanying TDP-43 accumulation, i.e., FTLD-TDP, the active ingredient of which essentially comprises at least one compound selected from the group consisting of cycloserine, terizidone, and salts thereof.

The invention discloses a novel cycloserine intermediate compound and a novel process route for preparing a cycloserine derivative. The compound is simple and convenient to synthesize and easy to control, when the intermediate compound is used for preparing the cycloserine derivative, the process route is simple and convenient, the reaction condition is mild, the operation process is simple and convenient, the production cost is low, and the prepared cycloserine derivative has relatively high purity and high yield.